Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 11/20 | 0.42 |
| ▸ | MMP13 | P45452 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6011960 | 0.74 | KMT2A (0.60) | ADAM17MMP13SLC6A4MMP9MMP8 | |
| SCHEMBL1118041 | 0.67 | CA12 (0.46) | ADAM17MMP13MMP9MMP8 | |
| SCHEMBL5085943 | 0.65 | SLC6A3 (0.48) | SLC6A2SLC6A4SLC6A3MMP1 | |
| SCHEMBL6323515 | 0.64 | SLC6A2 (0.45) | MMP13SLC6A2SLC6A4SLC6A3MMP1 | |
| SCHEMBL6011648 | 0.64 | SLC6A4 (0.42) | ADAM17MMP13SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17889804 | 0.64 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL6011657 | 0.64 | SLC6A4 (0.41) | ADAM17MMP13SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10951067 | 0.63 | CA12 (0.42) | ADAM17MMP13SLC6A4 | |
| SCHEMBL353884 | 0.62 | SLC6A3 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5717327 | 0.62 | SLC6A3 (0.40) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189650-A1 | Novel piperidine derivatives as modulators of chemokine receptor ccr5 | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189650-A1 | Novel piperidine derivatives as modulators of chemokine receptor ccr5 | CCR5, CCR2, CCR1 | ADAM17 2639/4885MMP13 2063/4885SLC6A2 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.